Key result
Severe obstructive sleep apnea was associated with significantly lower serum vaspin levels compared to healthy controls (0.69 vs 1.24 ng/mL, p=0.034), with no significant difference in lipocalin-2.
Why the study?
Does severe obstructive sleep apnea syndrome alter serum levels of vaspin and lipocalin-2 compared to healthy controls?
Case-Control (n=59)
No
Does severe obstructive sleep apnea syndrome alter serum levels of vaspin and lipocalin-2 compared to healthy controls?
Absolute Event Rate: 0.69% vs 1.24%
p-value: p=0.034
Severe obstructive sleep apnea is associated with decreased serum vaspin levels, suggesting a potential role for this adipocytokine in the metabolic dysregulation observed in OSAS.
No clinical action warranted in OSA; leaves open vaspin's mechanistic role in metabolic dysregulation.
BACKGROUND: Vaspin and lipocalin-2 are less-known recent members of adipocytokine family. There are ongoing studies investigating the role of vaspin ve lipocalin-2 in metabolic syndrome (MS). Obstructive sleep apnea syndrome (OSAS) is independently associated with an increased prevalence of MS. We aimed to measure the levels of vaspin and lipocalin-2 which are secreted from adipocytes in patients with severe OSAS and examine the relationship between these two adipocytokines and OSAS. METHODS: THE STUDY CONSISTED OF TWO GROUPS: severe OSAS patients with an apnea-hypopnea index (AHI) of >30/h (OSAS group, 34 subjects) and age-matched healthy volunteers with a AHI <5/h (control group, 25 subjects) Serum levels of vaspin and lipocalin-2 in these two groups were compared. RESULTS: Serum levels of vaspin were significantly lower in OSAS group; patients with severe OSAS compared with control group; healthy volunteers (OSAS group: 0.69±0.5 vs. control group: 1.24±1.13; P=0.034). The difference between the two groups in terms of serum levels of lipocalin-2 has not reached statistical significance (OSAS group: 61.6±18.2 vs. control group: 68.5±20.1; P=0.17). CONCLUSIONS: We found that serum vaspin levels were significantly lower in patients with severe OSAS compared with healthy controls. Lipocalin-2 levels were similar. The decrease in serum vaspin levels in severe OSAS patients may be important in diagnosis and follow-up of these patients.
No takes yet. Share an insight, caveat, or question.
Kıskaç et al. (2014) conducted a case-control in Severe Obstructive Sleep Apnea Syndrome (OSAS) (n=59). Severe Obstructive Sleep Apnea vs. Healthy volunteers (AHI <5/h) was evaluated on Serum vaspin levels (ng/mL) (p=0.034). Severe obstructive sleep apnea was associated with significantly lower serum vaspin levels compared to healthy controls (0.69 vs 1.24 ng/mL, p=0.034), with no significant difference in lipocalin-2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: